BB-MPI-03 + sargramostim + Montanide

**BB-MPI-03 + sargramostim + Montanide** is a combination immunotherapy regimen currently in Phase I development for hematologic malignancies. BB-MPI-03 is a multi-peptide cancer vaccine targeting *oncofetal antigen (OFA)*, designed to stimulate cytotoxic T cell responses against cancer cells. The regimen uses **sargramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF) as an immuno-adjuvant to boost antigen presentation and immune activation, and **Montanide** as an oily adjuvant to enhance vaccine formulation and immunogenicity. The goal is to promote a robust anti-tumor immune response in patients with stable or better disease status in acute myeloid leukemia (AML), multiple myeloma (MM), smoldering multiple myeloma (sMM), or myelodysplastic syndromes (MDS) who are off treatment or not eligible for transplant[1][4][3][8].

Other names

OFA multi-peptide cancer vaccineImmature laminin receptor protein multi-peptide cancer vaccineOFA multi-peptide immunotherapy